Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans

Psychopharmacology

Volumn 136, Issue 3, 1998, Pages 217-225

  Amass, Leslie ^a   Bickel, Warren K ^a,b   Crean, John P ^a   Blake, Joan ^a   Higgins, Stephen T ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

Alternate day dosing; Buprenorphine; Heroin; Human; Methadone; Reinforcer

Indexed keywords

BUPRENORPHINE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PRIORITY JOURNAL; REINFORCEMENT; SUBLINGUAL DRUG ADMINISTRATION; WITHDRAWAL SYNDROME;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; PATIENT DROPOUTS; PSYCHIATRIC STATUS RATING SCALES; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 0031891662     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050559     Document Type: Article

References (44)

1. Amass L, Bickel WK, Higgins ST, Hughes JR, Peterson T (1993) Detectability of buprenorphine dose alterations in opioid-dependent humans. In: Harris LS (ed) Problems of drug dependence 1992 (National Institute on Drug Abuse research monograph 132). Government Printing Offiee, Washington, DC, p 335
2. Amass L, Bickel WK, Higgins ST, Badger GJ (1994a) Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sci 54 : 1215-1228
3. Amass L, Bickel WK, Higgins ST, Hughes JR (1994b) A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J Addict Dis 13 : 35-47
4. Ball JC, Ross A (1991) The effectiveness of methadone maintenance treatment. Springer, New York
5. Bickel WK, Amass L (1995) Buprenorphine treatment of opioid dependence: a review. Exp Clin Psychopharmacol 3 : 477-489
6. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE (1988a) Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 247 : 47-53
7. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE (1988b) A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 43 : 72-78
8. Bickel WK, Amass L, Crean JP, Higgins ST (1995) Triple buprenorphine maintenance doses maintain opioid-dependent outpatients for 72 hours with minimal withdrawal. In: Harris LS (ed) Problems of drug dependence 1994 (National Institute on Drug Abuse research monograph 153). Government Printing Office, Washington, DC, p 161
9. Chiang CN, Hawks R (1994) Development of a buprenorphine-naloxone combination drug for the treatment of drug addiction. In: Harris LS (ed) Problems of drug dependence 1993 (National Institute on Drug Abuse research monograph 141). Government Printing Office, Washington, DC, p 458
10. Chiang CN, Bridge P, Creedon K, Hawks RL, Herbert S, Hill J, Maghrablian L, Terrill J, Walsh R (1996a) Buprenorphine-naloxone combination product for treating opioid addiction (abstract). Proceedings of the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence, June 22 27, San Juan, Puerto Rico
11. Chiang CN, Bridge P, Hawks RL, Herbert S, Hill J, Maghrablian L, Terrill J, Walsh R (1996b) The development of buprenorphine-naloxone products for treating opiate dependence. In: Harris LS (ed) Problems of drug dependence 1995 (National Institute on Drug Abuse research monograph 162). Government Printing Office, Washington, DC, p 117
12. Dennis ML, Ingram PW, Burks ME, Radial JV (1994) Effectiveness of streamlined admissions to methadone treatment: a simplified time-series analysis. J Psychoact Drugs 26 : 207-216
13. Fudala PJ, Jaffe JH, Dax EM, Johnson RE (1990) Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 47 : 525 - 534
14. Goldman FR, Thistel CI (1978) Diversion of methadone: illicit methadone use among applicants to two metropolitan drug abuse programs. Int J Addict 13:855-862
15. Gray RF, Ferry A, Jauhar P (1989) Emergence of buprenorphine dependence. Br J Addict 84:1373-1374
16. Himmelsbach CK (1939) Studies of certain addiction characteristics of (a) dihydromorphone. J Pharmacol Exp Ther 67:239-249
17. Iguchi MY, Stitzer ML, Bigelow GE, Liebson IA (1988) Contingency management in methadone maintenance: effects of reinforcing and aversive consequences on illicit polydrug use. Drug Alcohol Depend 22:1-7
18. Jasinski DR (1977) Assessment of the abuse potentiality of morphine like drugs (methods used in man). In: Martin WR (ed) Drug addiction I. Springer, New York, pp 197-258
19. Jasinski DR, Pevnick JS, Griffith JD (1978) Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiatry 35:501-516
20. Johnson RE, Cone EJ, Henningfield JE, Fudala PJ (1989) Use of buprenorphine in the treatment of opioid addiction. I. Physiologic and behavioral effects during a rapid dose induction. Clin Pharmacol Ther 46:335-343
21. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE (1995) Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend 40:27-35
22. Kirn TF (1988) Methadone maintenance treatment remains controversial even after 23 years of experience. JAMA 260: 2970-2975
23. Lange WR, Fudala PJ, Dax EM, Johnson RE (1990) Safety and side-effects of buprenorphine in the clinical management of heroin addiction. Drug Alcohol Depend 26:19-28
24. Martin W, Sloan JW, Sapiro JD, Jasinski DR (1971) Physiologic, subjective, and behavioral effects of amphetamine, metamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin Pharmacol Ther 12:245-258
25. Mendelson J, Jones RT, Fernandez I, Welm S, Melby AK, Baggott MJ (1996) Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clin Pharmacol Ther 60:105-114
26. Mendelson J, Jones RT, Welm S, Melby AK, Brown J, Batki SL (1997) Buprenorphine and naloxone interactions in methadone maintenance patients. Biol Psychiatry 41:1095-1101
27. Milby JB, Garrett C, English C, Fritschi O, Clarke C (1978) Take-home methadone: contingency effects on drug-seeking and productivity of narcotic addicts. Addict Behav 3:215-220
28. New-man RG, Peyser N (1991) Methadone treatment: experiment and experience. J Psychoact Drugs 23:15-121
29. O'Connor JJ, Moloney E, Travers R, Campbell A (1988) Buprenorphine abuse among opiate addicts. Br J Addict 83:1085-1087
30. Pickworth WB, Johnson RE, Holicky BA, Cone EJ (1993) Subjective and physiologic effects of intravenous buprenorphine in humans. Clin Pharmacol Ther 53:570-576
31. Quigley AJ, Bredemeyer DE, Scow SS (1984) A case of buprenorphine abuse. Med J Aust 142:425-426
32. Rance MJ, Dickens JN (1978) The influence of drug-receptor kinetics on the pharmacological and pharmaco-kinetic profiles of buprenorphine. In: Van Ree JM, Pereniums L (eds) Characteristics and function of opioids. Elsevier/North-Holland, Amsterdam, pp 65-66
33. Rosen MI, Wallace EA, McMahon TJ, Pearsall HR, Woods SW, Price LH, Kosten TR (1994) Buprenorphine: duration of blockade of effects of intramuscular hydromorphone. Drug Alcohol Depend 35:569-580
34. Sakol MS, Stark C, Sykes R (1989) Buprenorphine and temazepam abuse by drug takers in Glasgow an increase. Br J Addict 84:439-441
35. SPSS (1988) SPSSX User's guide 3rd edn. SPSS, Chicago, III.
36. Stitzer ML, Bigelow GE, Lawrence C, Cohen J, D'Lugoff B, Hawthorne J (1977) Medication take-home as a reinforeer in a methadone maintenance program. Addict Behav 2:9-14
37. Stitzer ML, Bigelow GE, Liebson IA, Hawthorne JW (1982) Contingent reinforcement for benzodiazepine-free urines: evaluation of a drug abuse treatment intervention. J Appl Behav Anal 15:493-503
38. Stitzer ML, Iguchi MY, Felch LJ (1992) Contingent take-home incentive: effects on drug use of methadone maintenance patients. J Consult Clin Psychol 60:927-934
39. Stitzer ML, Bigelow GE, Iguchi MY (1993) Behavioral interventions in the methadone clinic: contingent methadone take-home incentives. In: Harris LS (ed) Problems of drug dependence 1992 (National Institute on Drug Abuse research monograph 132). Government Printing Office, Washington, DC, p 66
40. Strain EC, Walsh SL, Preston KL, Liebson IA, Bigelow GE (1997) The effects of buprenorphine in buprenorphine-maintained volunteers. Psychopharmacology 129:329-338
41. Torrens M, San L, Cami J (1993) Buprenorphine versus heroin dependence: comparison of toxicologic and psychopathologic characteristics. Am J Psychiatry 150:822-824
42. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE (1994) Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 55:569-580
43. Walsh SL, Preston KL, Bigelow GE, Stitzer ML (1995) Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 274:361-372
44. Wenger LD, Rosenbaum M (1994) Drug treatment on demand Not. J Psychoact Drugs 26:1-11